NHS Digital. Cancer Survival in England. [cited 2023 May 26]. Available from https://digital.nhs.uk/data-and-information/publications/statistical/cancer-survival-in-england#resources.

Finnish Cancer Registry. Cancer Statistics. [cited 2023 May 26]. Available from https://cancerregistry.fi/statistics/cancer-statistics/.

Sheffield KM, Peachey JR, Method M, Grimes BR, Brown J, Saverno K, et al. A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer. Future Oncol. 2022;18:2667–82.

Article  CAS  PubMed  Google Scholar 

Cardoso F, van’t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast Cancer. N Engl J Med. 2016;375:717–29.

Article  CAS  PubMed  Google Scholar 

Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, et al. 21-Gene assay to inform Chemotherapy Benefit in Node-positive breast Cancer. N Engl J Med. 2021;385:2336–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-Gene expression assay in breast Cancer. N Engl J Med. 2018;379:111–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zahari S, Syafruddin SE, Mohtar MA. Impact of the Cancer Cell Secretome in driving breast Cancer progression. Cancers (Basel). 2023;15:2653.

Article  CAS  PubMed  Google Scholar 

Neagu AN, Whitham D, Buonanno E, Jenkins A, Alexa-Stratulat T, Tamba BI, et al. Proteomics and its applications in breast cancer. Am J Cancer Res. 2021;11:4006–49.

CAS  PubMed  PubMed Central  Google Scholar 

Fu Y, Li H. (2016). Assessing Clinical Significance of Serum CA15-3 and Carcinoembryonic Antigen (CEA) Levels in Breast Cancer Patients: A Meta-Analysis. Med Sci Monit, 22, 3154–3162 (2016).

Li X, Dai D, Chen B, Tang H, Xie X, Wei W. Clinicopathological and Prognostic Significance of Cancer Antigen 15 – 3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 Patients. Dis Markers, 2018, 9863092 (2018).

Strati A, Markou A, Kyriakopoulou E, Lianidou E. Detection and molecular characterization of circulating Tumour cells: challenges for the clinical setting. Cancers (Basel). 2023;15:2185.

Article  CAS  PubMed  Google Scholar 

Cescon DW, Kalinsky K, Parsons HA, Smith KL, Spears PA, Thomas A, et al. Therapeutic targeting of minimal residual disease to prevent late recurrence in hormone-receptor positive breast Cancer: challenges and New approaches. Front Oncol. 2022;11:667397.

Article  PubMed  PubMed Central  Google Scholar 

Deshmukh SK, Srivastava SK, Poosarla T, Dyess DL, Holliday NP, Singh AP, et al. Inflammation, immunosuppressive microenvironment and breast cancer: opportunities for cancer prevention and therapy. Ann Transl Med. 2019;7:593.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Danforth DN. The role of chronic inflammation in the development of breast Cancer. Cancers (Basel). 2021;13:3918.

Article  CAS  PubMed  Google Scholar 

Koh CH, Bhoo-Pathy N, Ng KL, Jabir RS, Tan GH, See MH, Jamaris S. Taib, N.A. Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer. 2015;113:150–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goto W, Kashiwagi S, Asano Y, Takada K, Takahashi K, Hatano T, et al. Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer. BMC Cancer. 2018;18:1137.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang L, Zhou Y, Xia S, Lu L, Dai T, Li A, Chen Y, Gao E. Prognostic value of the systemic inflammation response index (SIRI) before and after surgery in operable breast cancer patients. Cancer Biomark. 2020;28:537–47.

Article  CAS  PubMed  Google Scholar 

Brierley J, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th Edition. Hoboken: Wiley-Blackwell; 2016. pp. 151–159.

Jääskeläinen A, Roininen N, Karihtala P, Jukkola A. High parity predicts poor outcomes in patients with Luminal B-Like (HER2 negative) early breast Cancer: a prospective Finnish single-center study. Front Oncol. 2020;10:1470.

Article  PubMed  PubMed Central  Google Scholar 

Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JMS. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res. 2004;10:4793–8.

Article  CAS  PubMed  Google Scholar 

Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v8–30.

Article  PubMed  Google Scholar 

Friedman J, Hastie T, Tibshirani R. (2010). Regularization paths for generalized linear models via coordinate descent. J Stat Softw, 33, 1–22 (2010).

Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141–54.

Article  Google Scholar 

Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. JASA. 1999;94:496–509.

Article  Google Scholar 

Heagerty PJ, Zheng Y. Survival Model Predictive Accuracy ROC Curves Biometrics. 2005;61:92–105.

PubMed  Google Scholar 

Song X, Zhou XH. A semiparametric approach for the covariate specific Roc curve with survival outcome. Stat Sin. 2008;18:947–65.

Google Scholar 

Saraiva M, Vieira P, O’Garra A. Biology and therapeutic potential of interleukin-10. J Exp Med. 2020;217:e20190418.

Article  PubMed  Google Scholar 

Gunnarsdottir FB, Bendahl PO, Johansson A, Benfeitas R, Rydén L, Bergenfelz C, et al. Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study. Breast Cancer Res. 2023;25:29.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahmad N, Ammar A, Storr SJ, Green AR, Rakha E, Ellis IO, Martin SG. IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients. Cancer Immunol Immunother. 2018;67:537–49.

Article  CAS  PubMed  Google Scholar 

Kim JW, Lee S, Kim HS, Choi YJ, Yoo J, Park KU et al. Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10–13). Cytokine, 142, 155487 (2021).

Kim ES, Nam SM, Song HK, Lee S, Kim K, Lim HK, et al. CCL8 mediates crosstalk between endothelial colony forming cells and triple-negative breast cancer cells through IL-8, aggravating invasion and tumorigenicity. Oncogene. 2021;40:3245–59.

Article  CAS  PubMed  Google Scholar 

Chen B, Zhang S, Li Q, Wu S, He H, Huang J. Bioinformatics identification of CCL8/21 as potential prognostic biomarkers in breast cancer microenvironment. Biosci Rep. 2020;40:BSR20202042.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kamat K, Krishnan V, Dorigo O. Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer. Br J Cancer. 2022;127:1026–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hozhabri H, Moghaddam MM, Moghaddam MM, Mohammadian A. A comprehensive bioinformatics analysis to identify potential prognostic biomarkers among CC and CXC chemokines in breast cancer. Sci Rep. 2022;12:10374.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roderburg C, Labuhn S, Bednarsch J, Lang SA, Schneider AT, Hammerich L et al. Elevated Serum Levels of CCL23 Are Associated with Poor Outcome after Resection of Biliary Tract Cancer. Mediators Inflamm, 2022, 6195004 (2022).

Dobilas A, Åkesson A, Leandersson P, Borgfeldt CA. Multiplex biomarker assay improves the prediction of Survival in Epithelial Ovarian Cancer. Cancer Genomics Proteom. 2023;20:273–80.

Article  CAS  Google Scholar 

Gong DH, Chen YY, Ma D, Chen HY, Ding KF, Yu KD. Complicated prognostic values of CCL28 in breast cancer by subtype. J Thorac Dis. 2019;11:777–87.

Article  PubMed  PubMed Central  Google Scholar 

Wang X, Zhang Y, Wang S, Ni H, Zhao P, Chen G, et al. The role of CXCR3 and its ligands in cancer. Front Oncol. 2022;12:1022688.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu X, Sun A, Yu W, Hong C, Liu Z. CXCL10 mediates breast cancer tamoxifen resistance and promotes estrogen-dependent and independent proliferation. Mol Cell Endocrinol. 2022;512:110866.

Article  Google Scholar 

Jafarzadeh A, Fooladseresht H, Nemati M, Assadollahi Z, Sheikhi A, Ghaderi A. Higher circulating levels of chemokine CXCL10 in patients with breast cancer: evaluation of the influences of tumor stage and chemokine gene polymorphism. Cancer Biomark. 2016;16:545–54.

Article  CAS  PubMed  Google Scholar 

Narita D, Seclaman E, Anghel A, Ilina R, Cireap N, Negru S, et al. Altered levels of plasma chemokines in breast cancer and their association with clinical and pathological characteristics. Neoplasma. 2016;63:141–9.

Article  CAS  PubMed  Google Scholar 

Kwak T, Drews-Elger K, Ergonul A, Miller PC, Braley A, Hwang GH, et al. Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis. Oncogene. 2017;36:1559–72.

Article  CAS  PubMed  Google Scholar 

Palanissami G, Paul SFD. RAGE and its ligands: molecular interplay between glycation, inflammation, and Hallmarks of Cancer-a review. Horm Cancer. 2018;9:295–325.